The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow Transplant Program

Click Here for Details

Northside Hospital’s Blood and Marrow Transplant Program to Present Three Oral Presentations at the 58th Annual ASH Meeting and Exposition: Congratulations

The NSH-BMT Program physicians and clinical research team have once again been recognized by ASH for their commitment to participating in state-of-the-art blood and marrow clinical research trials.

NSH-BMT Program 2016 ASH Oral Presentations

1. Current graft-versus-host-disease (GVHD), relapse-free Survival – a novel, dynamic composite endpoint to better define effectiveness following allogeneic hematopoietic cell transplantation. Solomon S, Sizemore C, Ridgeway M, Zhang X, Solh M, Morris LE, Holland HK, Bashey A. ORAL ABSTRACT # 1170
2. Myeloablative allogeneic hematopoietic cell transplantation performed without routine inpatient admission: A single center experience of 462 consecutive patients. Bashey A, Zhang X, Brown S, Jackson K, Solh M, Lawrence M, Holland HK, Solomon S. ORAL ABSTRACT # 661
3. Comparison of peripheral blood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-Haploidentical donor transplantation using post-transplant cyclophosphamide. Bashey A, Zhang M, Mccurdy S, Ciurea S, St. Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, Hamandani M, Malki M, Munshi P, Nakamura R, O’donnell P, Perales M, Raj K, Rocha V, Romee R, Rowley S, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M. ORAL ABSTRACT # 683

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow Transplant and Leukemia Program

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow and Transplant Program

Click Here for Details

Northside Blood and Marrow Transplant Program Publishes Fall 2016 Newsletter

Click Here to read

Exceeding Survival Outcome Rates in Allogeneic and Unrelated Donor Transplants

For the seventh consecutive year (2009-15) NSH-BMT, achieved survival outcomes that significantly exceeded the expected range as reported in the 2015 Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor (NMDP) data release. There were 173 adult and pediatric transplant centers included in the analysis. *1, 2

1 Reported outcome data from bethematch.org. This survival information includes only patients who received their first allogeneic transplant between January 1, 2011 and December 31, 2013 using unrelated or related donors, and who had reported follow-up. 2 Final 2015 Transplant Center Specific Survival Report, December 16, 2015

Please go to Survival for additional NSH-BMT survival outcome data information.

Open to Enrollment: A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies

Click Here for Details

NSH-BMT Program Named as Core Clinical Transplant Center

NSH-BMT is the only transplant program in Georgia to receive the prestigious designation of Core Clinical Center from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). This designation is accompanied by a research grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The Program is one of 20 out of more than 120 such BMT Programs in the United States to be awarded this status.

[READ MORE]

New Acute Myelogenous Leukemia (AML) Allogeneic Consultation Timing Guidelines

The National Marrow Donor Program®/BeTheMatch and the American Society for Blood and Marrow Transplantation (ASBMT) have jointly developed a supplement to NCCN® Guidelines for the timing of Allogeneic Transplant Consultation for AML.1 New AML referral timing guidelines recommends high-resolution HLA typing be performed at time of diagnosis for all patients, and identifies those patients who should be referred early for transplant consultation after initial diagnosis. This includes all patients with intermediate and poor-risk cytogenetic/molecular features as well as high-risk disease features.

Transplant Consultation Guidelines for Adult AML
High-resolution HLA typing is recommended at diagnosis for all patients
Early after initial diagnosis, all AML patients should undergo evaluation for HCT, including:

  • CR1 - except favorable risk AML [defined as: t(16;16), inv 16, or t(8;21) without c-KIT mutation; t(15;17); normal cytogenetics with NPM1 or biallelic CEBPA mutation and without FLT3-ITD]
  • Antecedent hematological disease (e.g., myelodysplastic syndrome [MDS])
  • Treatment-related leukemia
  • Primary induction failure or relapse
  • Presence of minimal residual disease after initial or subsequent therapy
  • CR2 and beyond, if not previously evaluated
Please call (404) 255-1930 if you would like to discuss a leukemia referral with one of our physicians.

1. 2016 NMDP/BeTheMatch and ASBMT referral timing guidelines – AML.

Upcoming National Marrow Donor Program®/BeTheMatch CME Webinars for Physicians

To assist referring physicians on the latest research affecting clinical decisions, including the timing of referral for transplant consideration, NMDP®/BeTheMatch will be conducting three live CME webinars this fall. Webinar registration can be completed at https://bethematchclinical.org/resources-and-education/education-courses-and-events.

AML Risk Stratification: Influence of Emerging Cytogenetics and Molecular Markers on Treatment Decisions
Thursday, Sept. 29, 2016, 4-5 pm CDT

Speakers: Clara D. Bloomfield, M.D. (moderator), Jessica Altman, M.D., and Aaron Gerds, M.D.

Making AML Therapy Decisions at First Remission: Is Timing Everything?
Thursday, Oct. 20, 2016, 4-5 pm CDT

Speakers: Robert J. Soiffer, M.D. (moderator), Ellen Ritchie, M.D., and Roland Walter, M.D.

AML in Older Adults: Are Outcomes Age Dependent?
Thursday, Nov. 17, 2016, 4-5 pm CST

Speakers: Fred Appelbaum, M.D. (moderator), James Foran, M.D., and Laura C. Michaelis, M.D.

National Marrow Donor Program (NMDP): Post Transplant Mobile App is Now Available

To help physicians with the reference materials they need to care for transplant patients, The National Marrow Donor Program®/BeTheMatch has developed a free Transplant Guideline mobile app, available through the Apple© and AndroidTM app stores. For more information please visit https://bethematch.org/about-us/how-we-help-patients/transplant-education/ nmdpapp

Post- Blood and Marrow Transplant Immunization Schedule- What You Need to Know

After blood and marrow transplant, patients will need to be re-immunized with all childhood vaccinations due to their new immune systems being immature and vulnerable to diseases/infections. It is recommended that post-transplant patients begin their vaccination schedule six months after transplant unless clinically contraindicated. The Centers for Disease Control (CDC), recommends the following:

  • Inactivated influenza vaccine should be administered beginning at least 6 months after HCT and annually thereafter for the life of the patient.
  • Sequential administration of 3 doses of pneumococcal conjugate vaccine is recommended, beginning 3-6 months after the transplant, followed by a dose of PPSV.
  • A 3-dose regimen of Hib vaccine should be administered beginning 6 months after transplant; at least 1 month should separate the doses.
  • MMR vaccine should be administered 24 months after transplant if the HCT recipient is immunocompetent.
  • If a decision is made to vaccinate with varicella vaccine, the vaccine should be administered a minimum of 24 months after transplantation if the HCT recipient is presumed to be immunocompetent.
Please click here to view the NSH-BMT post-transplant vaccination schedule recommended for both autologous and allogeneic transplant recipients. For more specific information, see Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [1.9MB, 96 pages]. Biol Blood Marrow Transplant 15:1143-1238;2009 or visit http://www.cdc.gov/vaccines.

NSH - BMT’s Clinical Program, Collection Facility and Hematopoietic Stem Cell Processing Laboratory Receives a Perfect FACT (Foundation for Accreditation of Cellular Therapy) Inspection Score


In November 2015, the NSH - BMT Clinical Program, Collection Facility (Atlanta Blood Services) and the Hematopoietic Stem Cell Laboratory underwent the required three year FACT inspection. Each area was praised for their commitment to a culture of quality, patient safety and continuously striving for high patient satisfaction. We believe our continuous process improvement, open communication and focusing on improving patient care has resulted in superior survival outcomes. NSH-BMT’s clinical program has received perfect FACT inspection scores during their 2003, 2006, 2009, 2012, and 2015 inspections.

 

Ashlee Holbein, RN, FACT/QI Coordinator and Melissa Horowitz, RN, Supervisor of Program Quality & Clinical Coordinators

BMT Program Quality External Audits: FACT

Consecutive Inspections Resulted in ZERO Clinical Deficiencies

Congratulations to Northside Hospital BMT/Leukemia Program Physicians: Voted Atlanta Top Doctors

As seen in the July 2016 Atlanta Magazine, Drs. Asad Bashey, H.Kent Holland, Lawrence Morris, and Scott Solomon have been voted by their peers as Atlanta Top Doctors in Hematology and Oncology. Our Physicians lead a highly trained interdisciplinary team who provide outstanding quality patient centered care. This commitment to quality has resulted in exceptional survival outcomes and excellent patient/referring physician satisfaction.

The Top Doctor nominating process is conducted by Castle Connolly, a healthcare research and information company founded in 1991. Castle Connolly identifies the top doctors in America and provides consumers with detailed information about their education, training, and special expertise. Its online nominations process, castleconnolly.com/nominations, is open to all U.S. licensed physicians. Doctors do not and cannot pay to be selected and profiled as Castle Connolly Top Doctors.

Please visit the Atlanta Magazine Top Doctor edition at http://www.atlantamagazine.com/top-doctors/

Margaret Marcinkowski: Eighteen Years with the NSH BMT/Leukemia Program: A life of Hope and Wellness

Margaret's family in 1998 and in 2015

I had been feeling unwell for a few weeks. I had multiple issues, but it had come on gradually, so I wasn’t clear how sick I was. I was diagnosed with Acute Meylogenous Leukemia in June of 1998. I remember going to the hospital the night before my leukemia diagnosis. I was 36 years old, married and a mother of three small children ages 8, 5 and 1. The evening after I was diagnosed I was admitted to Northside Hospital. I was introduced to Dr. Gerry Connaghan and Dr. Kent Holland, who were opening their practice, The Blood and Marrow Transplant Group of Georgia at Northside Hospital. Suddenly, I felt like my luck was changing. I could be treated at Northside Hospital’s BMT/Leukemia programs and be treated by extraordinary experts in their field.

To read more of Margaret’s story, please click here.

NSH- BMT/Leukemia Patient Craig Sager’s Message of Hope

TNT's Inside the NBA Interview

NSH-Leukemia Program’s Patient Katherine Welch Featured in July 2016 Atlanta Magazine

The July 2016 Atlanta Magazine issue featured our Northside Leukemia patient Katherine Welch’s expose on her Acute Leukemia diagnosis, delivery of her first child, and her unique outlook on life after her cancer diagnosis. Please click here.

On October 13, 2015, NSH-Leukemia Physician, Dr. Asad Bashey, spoke to 11 Alive News about Katherine Welch, a newly diagnosed NSH - Leukemia patient, who is twenty four weeks pregnant and undergoing lifesaving chemotherapy treatment for herself and unborn child.

With access to state-of-the-art diagnostic testing, comprehensive patient-centered care, and bone marrow transplant services, the NSH- Leukemia Program provides patients with the exceptional quality care needed to treat their blood-related malignancy. Please go to Leukemia for additional information.

Platelet Donation Video - Atlanta Blood Services

Hesitant about donating platelets? Our wonderful platelet hero Dave takes the guesswork out of donating! The process is very similar to donating whole blood, and with your donation you are giving the gift of life to an active blood cancer or blood disorder patient right here in Atlanta!

Call 404-459-8744 and schedule your appointment to save lives today!

Click here to view video

ncccp

The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.